Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer
Study Details
Study Description
Brief Summary
This is a multi-center, prospective, interventional, single-arm clinical trial. In the study, patients with her2-positive recurrent or metastatic breast cancer who were initially treated were included. The purpose of this study is to evaluate the efficacy and safety of Inetetamab combined with anti-PD-1 monoclonal antibody and albumin-bound paclitaxel for HER2+ Metastatic Breast Cancer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Detailed Description
This is a multi-center, prospective, interventional, single-arm clinical trial. In the study, patients with her2-positive recurrent or metastatic breast cancer who were initially treated were included. The purpose of this study is to evaluate the efficacy and safety of Inetetamab combined with anti-PD-1 monoclonal antibody and albumin-bound paclitaxel for HER2+ Metastatic Breast Cancer.To explore a new concept of anti-HER2 monoclonal antibody combined with immunotherapy in the treatment of recurrent or metastatic breast cancer. The primary end point is progression free survival (PFS). The secondary end points are objective response rate (ORR), Clinical Benefit Rate (CBR) and safety assessment.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Inetetamab+ Toripalimab+ Albumin-Bound Paclitaxel Drug: Inetetamab Initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30 to 90 minutes IV infusion every three weeks Drug: Toripalimab 240mg intravenously every 3 weeks Drug: Albumin-Bound Paclitaxel 130mg/m2, IV , D1, D8, q3w |
Drug: Inetetamab
Initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30 to 90 minutes IV infusion every three weeks
Drug: Toripalimab
240mg intravenously every 3 weeks
Drug: Albumin-Bound Paclitaxel
130mg/m2, IV , D1, D8, q3w
|
Outcome Measures
Primary Outcome Measures
- Progression free survival (PFS) [Assessed up to approximately 24 months]
PFS is defined as the time from the date of the first dose until first evidence of disease progression or death based on investigator assessment using RECIST 1.1 and irRECIST.
Secondary Outcome Measures
- Objective response rate (ORR) [Assessed up to approximately 24 months]
ORR is defined as the percentage of participants who have a complete response (CR) or partial response (PR) based on CT/MRI, investigator assessment using RECIST 1.1 and irRECIST.
- Clinical benefit rate (CBR) [Assessed up to approximately 24 months]
CBR is defined as the percentage of evaluable participants with best objective response of confirmed complete response or partial response per RECIST 1.1 and irRECIST, or prolonged stable disease (≥ 6 months).
- Safety assessment (AEs and SAEs) [From the time of inform consent form signature until 30 days after end of treatment]
Adverse Events (AEs) and Serious Adverse Events (SAEs)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Female patients aged > 18 years.
-
Pathological diagnosis of HER-2 was positive (definition: immunohistochemical results were + + + or ICH++ with fluorescence in situ hybridization results were positive).
-
Participants must have histologically or cytologically confirmed invasive breast cancer with locally recurrent or radiological evidence of metastatic disease.
-
Patients with locally recurrent inoperable or metastatic HER2-positive breast cancer:
-
patients with metastatic breast cancer at the time of initial diagnosis, meaning there was no previous history of breast cancer in the past; or
-
patients with Locally recurrent or metastatic breast cancer, neoadjuvant/adjuvant anti-HER2 therapy has been completed for ≥6 months.
-
HER2-positive recurrent or metastatic BC patients who have received at most one anti-HER2 therapy after diagnosis;.
-
PD-L1-positive (cut-off ≥ 1% stained cells);
-
Patients with assessable target lesion as per RECIST 1.1 and irRECIST criteria.
-
ECOG PS score 0 or 1, estimated survival time ≥3 months, and can be followed-up.
-
Cardiopulmonary function is basically normal.
-
Liver function is basically normal.
-
Have sufficient baseline hematology parameters.
-
Coagulation Indicators: International normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5 times the upper limit of normal, unless drugs known to change INR and aPTT are used.
-
No history of serious heart, kidney and other important organs and endocrine disease.
-
Female patients of childbearing age have a negative pregnancy test and voluntarily take effective and reliable contraceptive measures.
-
The patients voluntarily signed an informed consent form.
Exclusion Criteria:
-
Participated in other clinical trials within 4 weeks;
-
Evidence of symptomatic central nervous system metastasis or pia mater disease.
-
History of receiving CD137 agonists or checkpoint blockade therapy (including anti-CD40, anti-CTLA-4, anti-PD-1, anti-PD-L1 monoclonal antibody therapy).
-
History of receiving paclitaxel for injection (Albumin Bound) in first-line chemotherapy for advanced disease.
-
History of autoimmune disease Including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease (IBD), etc.
-
Immunosuppressive drugs required within 2 weeks before enrollment or during this study. The following conditions are excluded: 1) intranasal, inhalation, topical or local steroid injection (e.g., intra articular injection); 2) physiological doses of systemic corticosteroids (≤ 10 mg/day prednisone or equivalent dose); 3) short term (≤ 7 days) use of steroids to prevent or treat non-autoimmune allergic diseases.
-
History of acute or chronic hepatitis B virus (HBV), or hepatitis C virus (HCV).
-
History of primary or acquired immunodeficiency (including HIV-positive).
-
History of hypersensitivity to the study medication
-
Pregnancy or lactation.
-
History of myocardial infarction within 6 months before enrollment, congestive heart failure (New York Heart Association [NYHA] Classes ≥ II), severe arrhythmia beyond drug control, or a decrease in LVEF to < 50% with previous trastuzumab neoadjuvant or adjuvant treatment.
-
History of other malignant disease within 5 years (except cured of in-situ carcinoma of the cervix, basal cell carcinoma of the skin and squamous cell carcinoma).
-
Participants who were judged by the investigator to be unsuitable for this study .
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Cancer Hospital Chinese Academy Of Medical Sciences | Beijing | China |
Sponsors and Collaborators
- Chinese Academy of Medical Sciences
Investigators
- Principal Investigator: Binghe Xu, MD, Director of Breast Cancer Section
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SPT-2021-002